HER2-mutant NSCLC is associated with poor prognosis. Zongertinib and BAY 2927088 are HER2 tyrosine kinase inhibitors that have activity in NSCLC with manageable toxicity profiles.

This approval makes foscarbidopa/foslevodopa the first and only subcutaneous 24-hour infusion of levodopa-based therapy for adults with Parkinson disease.

Retail pharmacies benefit from the shift from a volume-centric model to a value-centric approach that focuses on enhancing patient care, reducing pharmacist burnout, and leveraging technology to improve efficiency and expand the scope of pharmacy services.

The guidelines emphasize the importance of vaccination, risk assessment, and preparedness for immunocompromised patients who are traveling post-transplant.

Questions in the pharmacy are endless and often hard to answer.

Measures like hassle-free safe sharps disposal packaging save critical staff time and resources.

The KEYNOTE-756 and CheckMate 7FL trials show this combination improves pathological complete response rates in this patient population.

Pharmacogenomic testing can help identify patients' genetic profiles, revealing why certain drugs may be less effective or cause adverse effects.

Cardiovascular diseases have a significant impact on brain health and function.

The increase was observed across multiple subgroups, including those with overweight or obesity and hospitalized patients.

Gepotidacin could be first-in-class oral antibiotic treatment approved for uUTIs in over 20 years.

The results indicate the potential use of loncastuximab tesirine as a treatment option for the rare hyperinflammatory condition.

Artificial intelligence holds immense potential to address the rising demand for oncology services and improve patient outcomes by facilitating more effective, efficient, personalized cancer care.

A projected shortage of trained staff in the years ahead demands looking beyond normal hiring channels.

The drug's safety profile included significant rates of nausea, vomiting, and hematologic toxicities like neutropenia and thrombocytopenia. Although promising, brigimadlin requires careful management of adverse effects, including antiemetic and hematologic support.

The updated recommendations include CGRP inhibitors as a first-line treatment option for chronic and episodic migraine prevention.

Advanced cell therapies are now saving the lives of people whose blood cancer would previously have been incurable. While the UK was quick to recognize the potential of these innovative therapies, patient access to these therapies may change without continued investment in the UK's cell therapy infrastructure.

Imuldosa has received approval for all indications of its reference product, including ulcerative colitis, psoriatic arthritis, and Crohn disease.

Glucocorticoids improved outcomes for patients with Kawasaki disease at high risk of IVIG resistance without glucocorticoid-related adverse effects.

Although respondents identified some exciting areas of growth, challenges remain, including the complex insurance system and ensuring patient medication adherence.

Current guidelines recommend a backbone of SLGT2 therapy in patients with HFpEF who have no contraindications.

Investigators state that health care providers should consider the potential use of 2 doses to increase the effectiveness against influenza B.

Legislative efforts in the states and Washington, DC, have made progress, but there is still a way to go.